- Adult patients (age ≥18 years old).
- Patients suffering from AATD treated by Respreeza® through a peripheral vein at home for at least 3 month (consecutives or not). The 3-month period of treatment with Respreeza® does not necessarily correspond to the 3 months prior to inclusion.
- Patient accompanied by a third person at home
- Patients deemed to be suitable by the investigator for self-administration.
- Patients with a life expectancy of over 3 years.
- Patients who have been informed verbally and in writing via the information leaflet and who have signed the informed consent form.
Alpha-1 Antitrypsin Deficiency
According to the Respreeza® Summary of Product Characteristics, the initial infusions must be administered under the supervision of a health professional experienced in the treatment of alpha-1 antitrypsin deficiency, although subsequent infusions may be administered at home by the person responsible for care or by the patient. Clinical data on self-administration of Respreeza® are however limited and the grounds for self-administration are left to the assessment of the attending physician, who needs to ensure that appropriate training is delivered. In this context, CSL Behring would like to run a clinical study in order to assess the effectiveness of a home self-administration learning program in terms of switching to self-administration, and the long term maintenance of this administration.
If interested, contact email@example.com for more information
Study Eligibility Criteria
- - In order to reflect the reality of everyday practice, no non-inclusion criteria are intended except for patient refusal to take part in the study.